At this point, every AbbVie (NYSE:ABBV) investor knows about the company's reliance on its blockbuster drug Humira. The drug accounts for around half of the company's total sales and was one of its main growth drivers last quarter. While most investors are wondering what will happen to this drug's sales after it loses patent protection in 2016, some may forget that the company has other drugs that are poised to lose market exclusivity in the coming years. In the following segment, health care analysts David Williamson and Max Macaluso discuss the upcoming patent expirations that AbbVie investors need to watch.
The relevant video segment can be found between 5:10 and 6:59.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What AbbVie's Management Just Said About Its Future
The manufacturer of the world's best-selling drug is offering up a very optimistic forecast.
7 Must-See Numbers From AbbVie's J. P. Morgan Presentation
AbbVie CEO Rick Gonzalez called the biotech "a unique investment opportunity." These numbers show why he's right.
Is AbbVie Stock Still A Strong Buy?
AbbVie's shares crushed the broader markets in 2017. Can this top biopharma stock keep pushing higher this year?